📰 Valuating News
Page 10 - Valuating News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Valuating. Real-time updates on events, politics, business and more.
January 16, 2023
Positive results on primary and secondary endpoints, identifying dose for future development Direct and significant effect of CER-001 on endotoxin removal and consequent reduction in the inflammatory
January 11, 2023
ROCKVILLE, MD and SHENZHEN, CHINA, Jan 11, 2023 - (ACN Newswire) - HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional
January 9, 2023
ND0612, a continuous 24 hours/day subcutaneous (SC) infusion?of liquid levodopa/carbidopa (LD/CD), showed superior efficacy compared to oral LD/CD for the primary endpoint ("ON" time without
January 4, 2023
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2, randomized, placebo-controlled trial to evaluate its development-stage medicine daxdilimab, a potentially
January 3, 2023
MUEHLHEIM (dpa-AFX) - Univar Solutions Inc. (UNVR) confirmed Monday that Brenntag (BNTGF.PK) has ended its discussions with the company about a potential acquisition.Univar said it will continue
January 3, 2023
DOWNERS GROVE, Ill., Jan. 3, 2023 /PRNewswire/ -- Univar Solutions Inc. (NYSE: UNVR) ("Univar" or "the Company"), a leading global solutions provider to users of specialty ingredients and chemicals
January 3, 2023
VANCOUVER, BC / ACCESSWIRE / January 3, 2023 / WEX Pharmaceuticals Inc. ("WEX" or the "Company"), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that the first
December 27, 2022
U.S. carrier United Airlines Holdings Inc said on Tuesday it is currently evaluating the market demand and operating environment to determine when to resume additional flight operations to... | December 27, 2022
December 11, 2022
Epcoritamab featured in multiple data disclosures, including four oral presentations Results presented from the phase 1b/2 EPCORE NHL-2 trial of epcoritamab combined with standard salvage
December 8, 2022
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first subject has been dosed in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics